1. India Stocks

  2. •

    Technology services

  3. •

    Packaged software
iSERA Lifesciences Limited

iSERA Lifesciences Limited

BBSE:ISERA
143.90
INR
0.00
(0.00%)
-0.10EPS
1.09BMarket Cap
iSERA Lifesciences Limited
BSE:ISERA
(Bombay Stock Exchange)

Recent

price

143.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
5,590.99
5,828.23
8,127.75
11,286.66
3,479.34
8,017.63
7,558.67
14,681.79
3,867.66
670.79
670.79
- -
- -
- -
8.2
1.61
2.12
Revenue per Share
54.73
56.58
606.83
33.27
40.56
-4,219.69
-10.97
3.33
-4.93
-131.3
559.71
-1,172.35
-1,241.84
-3.14
3.65
0.31
-0.1
Basic EPS, GAAP
-7.93
-28.85
-3,110.22
-1,051.68
28.54
130.06
-382.14
-354.16
107.96
305.9
1,397.88
-3,333.46
-1,370.62
-2.02
-43.32
-6.37
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
4,873.08
4,929.65
4,319.77
4,353.13
4,393.69
173.99
163.03
165.42
163.67
35.36
-33.35
- -
-1,291.97
-6.68
-3.03
9.81
- -
Book Value per Share
4,873.08
4,929.65
2,916.29
2,949.65
2,990.21
173.99
163.03
165.42
163.67
35.36
-33.35
- -
-1,291.97
-6.68
-3.03
9.81
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
8
6
Basic Weighted Avg Shares
60
63
258
359
111
255
240
336
123
21
21
- -
- -
- -
3
14
14
Sales/Revenue/Turnover
1.42
1.43
11.5
0.54
1.04
0.26
0.45
0.85
1.92
-8.3
85.12
- -
- -
- -
52.38
19.65
-3.62
Operating Margin (%)
- -
- -
2
3
7
1
3
2
1
1
1
- -
- -
- -
- -
- -
- -
Depreciation Expense
1
1
19
1
1
-134
- -
- -
- -
-4
18
-1
-1
-1
1
3
-1
Net Income, GAAP
30.82
32.24
35.06
45.09
- -
- -
- -
47.12
280.16
- -
1
- -
- -
- -
14.97
22.89
493.59
Effective Tax Rate (%)
0.98
0.97
7.47
0.29
1.17
-52.63
-0.15
0.02
-0.13
-19.57
83.44
- -
- -
- -
44.53
19.14
-4.53
Profit Margin (%)
4
5
40
76
79
58
71
77
57
61
15
- -
- -
- -
3
37
- -
Working Capital
- -
- -
24
56
63
59
72
78
59
66
20
- -
1
2
16
17
- -
LT Debt
53
53
137
138
140
6
5
5
5
1
-1
- -
-1
-2
-1
82
- -
Total Equity
1.13
1.15
18.03
0.59
- -
- -
- -
1.56
-4.71
- -
41.88
- -
- -
- -
15.78
3.55
- -
Return on Invested Capital (%)
1.13
1.15
18.03
0.59
- -
- -
- -
1.41
-4.49
- -
41.87
- -
- -
- -
16
4.54
- -
Return on Capital (%)
1.13
1.15
20.25
0.77
0.93
-184.76
-6.51
1.46
-2.99
-131.94
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
- -
- -
LT Borrowings
- -
17
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
8
8
8
Market Capitalization
143
464
1,086

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
43
- -
Cash, Cash Equivalents & STI
- -
29
- -
Accounts Receivable, Net
- -
12
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
7
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-638.02%
-1,220.58%
-8,515.51%
Free Cash Flow
224.55%
454.96%
281.98%
Net Income, GAAP
128.96%
-44.29%
119.64%
Sales/Revenue/Turnover
- -
- -
410.94%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
3
2026
- -
- -
2
12
14
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-0.35
-0.07
-2.06
7.13
3.65
2026
-0.48
0.22
-0.34
0.65
0.31
2027
-0.4
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -
Similar Companies
Microsoft Corporation (NASDAQ:MSFT)
Palantir Technologies Inc. (NASDAQ:PLTR)
Nebius Group N.V. (NASDAQ:NBIS)
Oracle Corporation (NYSE:ORCL)
CoreWeave, Inc. (NASDAQ:CRWV)
ServiceNow, Inc. (NYSE:NOW)
Business
iSERA Lifesciences Limited is a biotechnology and biopharmaceutical company based in India, specializing in the research, development, manufacturing, and commercialization of lifesaving biologicals, therapeutic antisera, and equine-derived immunoglobulins. The company provides a comprehensive portfolio of specialized biotherapeutic products, including Polyvalent Snake Venom Antiserum formulated for Indian and African snake species; Scorpion Venom Antiserum; Rabies Antiserum for post-exposure prophylaxis; Diphtheria Antitoxin for infectious disease management; Tetanus Antitoxin; pooled equine hyper-immune plasma; and specialized antiserum formulations for emergency healthcare interventions. iSERA Lifesciences operates biomanufacturing, plasma processing, and research facilities located in Shirala, Sangli District, Maharashtra, supplying institutional healthcare providers, government health procurement programs, hospitals, and commercial export markets across Asia and Africa. Originally incorporated in 1993 and headquartered in Pune, Maharashtra, India, the company has recently completed major corporate restructurings to transition from legacy information technology services into a dedicated biopharmaceutical enterprise. In April 2026, the company officially changed its corporate name from Covidh Technologies Limited to iSERA Lifesciences Limited and relocated its registered office from Hyderabad, Telangana, to Pune, Maharashtra. In addition, the company approved the strategic acquisition of a 100 percent equity stake in iSERA Biological Limited through a share swap agreement, fully integrating biological manufacturing infrastructure, equine immunization assets, and advanced research and development programs into its core corporate structure.